Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 1.34 -1.47% -0.02
RIGL closed down 1.47 percent on Monday, March 18, 2024, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -1.47%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
Fell Below 50 DMA about 21 hours ago
50 DMA Support about 21 hours ago
Down 3% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rigel Pharmaceuticals, Inc. Description

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Autoimmune Disease Chemical Compounds Phosphates Drug Development Ophthalmic Enzymes Rheumatoid Arthritis Asthma Cancer Cell Tyrosine Kinase Lupus Adenosine Protein Kinase Tyrosine Kinase Inhibitors Inflammatory And Autoimmune Diseases Janus Kinase Daiichi Sankyo Discoid Lupus Erythema Muscle Disorders Portola Pharmaceuticals Syk Tyrosine Kinases

Is RIGL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.96
52 Week Low 0.712
Average Volume 1,137,622
200-Day Moving Average 1.22
50-Day Moving Average 1.33
20-Day Moving Average 1.43
10-Day Moving Average 1.46
Average True Range 0.11
RSI (14) 46.24
ADX 30.07
+DI 24.30
-DI 19.38
Chandelier Exit (Long, 3 ATRs) 1.41
Chandelier Exit (Short, 3 ATRs) 1.43
Upper Bollinger Bands 1.68
Lower Bollinger Band 1.17
Percent B (%b) 0.33
BandWidth 36.30
MACD Line 0.03
MACD Signal Line 0.05
MACD Histogram -0.0235
Fundamentals Value
Market Cap 233.66 Million
Num Shares 174 Million
EPS -0.14
Price-to-Earnings (P/E) Ratio -9.57
Price-to-Sales 1.62
Price-to-Book 31.64
PEG Ratio -0.10
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.42
Resistance 3 (R3) 1.41 1.39 1.40
Resistance 2 (R2) 1.39 1.37 1.39 1.40
Resistance 1 (R1) 1.36 1.36 1.35 1.37 1.39
Pivot Point 1.34 1.34 1.33 1.34 1.34
Support 1 (S1) 1.31 1.32 1.30 1.32 1.29
Support 2 (S2) 1.29 1.31 1.29 1.28
Support 3 (S3) 1.26 1.29 1.28
Support 4 (S4) 1.27